Background
Methods
Study design and data source
Study population
Seasonal influenza vaccine uptake
Characteristics of the study population
Statistical analysis
Results
Study population characteristics (Table 1)
2006/07 (n = 17,259) | 2015/16 (n = 11,440)a | |
---|---|---|
%b | %b | |
Sociodemographic characteristics | ||
Age (years) on 12.31.n – mean (SD) | 65.0 (13.7) | 70.5 (12.8) |
Women | 46.1 | 47.1 |
Clinical characteristics | ||
Type and treatment of diabetes | ||
Type 1 diabetesc | 9.2 | 11.2 |
Other types -- no antidiabetic drug | 15.8 | 9.2 |
Other types - only one noninsulin antidiabetic drug | 35.3 | 22.0 |
Other types -- ≥ 2 noninsulin antidiabetic drugs | 28.2 | 33.6 |
Other types -- insulin treatment ± antidiabetic drugs | 11.5 | 24.0 |
Weighted individual chronic condition scored – mean (SD) | 0.8 (0.5) | 0.9 (0.5) |
Annual rate of hospitalization for diabetes or its complicationse | 6.2 | 4.3 |
Annual rate of hospitalization for influenza or its complicationse | 0.7 | 1.4 |
Healthcare utilization | ||
Annual number of consultationsf with -- mean (SD) | ||
General practitioner | 8.6 (7.3) | 7.9 (6.4) |
Endocrinologist | 0.3 (1.2) | 0.4 (1.2) |
Cardiologist | 0.5 (1.5) | 0.5 (1.4) |
Change of general practitioner | 4.0 | 10.3 |
Received free vaccination voucher for diabetesg | 69.9 | 90.3 |
SIV-uptake trajectories (Fig. 1)
Risk factors for SIV-uptake trajectory memberships
Trajectory (ref. 1. Continuously vaccinated - n = 4344 (27.6%) | |||||
---|---|---|---|---|---|
2. Progressively less vaccinated | 3. Post pandemic decreasingly vaccinated | 4. Early increasingly vaccinated | 5. Late increasingly vaccinated | 6. Never vaccinated | |
n = 2832 | n = 1627 | n = 1472 | n = 763 | n = 4728 | |
18.0% | 10.3% | 9.3% | 4.8% | 30.0% | |
Adjusted risk ratio [95% confidence interval] | |||||
Sociodemographic characteristics | |||||
Age at inclusion > 65 |
2.89 [2.47;3.33]
|
0.68 [0.60;0.78]
|
0.33 [0.28;0.38]
|
0.14 [0.11;0.18]
|
0.56 [0.52;0.61]
|
Women |
0.82 [0.75;0.91]
|
1.38 [1.26;1.51]
| 0.99 [0.88;1.10] | 0.98 [0.83;1.14] |
1.09 [1.05;1.14]
|
Clinical characteristics | |||||
Type and treatment of diabetes at inclusion | |||||
Type 1c | 0.99 [0.83;1.16] | 1.11 [0.95;1.30] |
0.76 [0.59;0.97]
|
0.53 [0.37;0.76]
|
0.85 [0.76;0.94]
|
Other types -- no antidiabetic drug |
1.18 [1.01;1.36]
|
1.61 [1.39;1.85]
|
3.04 [2.77;3.29]
|
2.10 [1.69;2.56]
|
1.62 [1.54;1.68]
|
Diabetes treatment intensificationd during follow-up |
0.76 [0.68;0.84]
| 1.04 [0.94;1.15] |
1.23 [1.09;1.39]
|
1.25 [1.06;1.47]
| 0.96 [0.91;1.01] |
Weighted individual chronic condition scoree at inclusion ≥ median |
1.16 [1.04;1.28]
|
0.87 [0.78;0.97]
|
0.77 [0.68;0.87]
|
0.81 [0.68;0.96]
|
0.75 [0.71;0.80]
|
Course of weighted individual chronic condition scoree during follow-up | |||||
Stable |
1.33 [1.06;1.60]
| 0.81 [0.55;1.13] | 0.68 [0.40;1.11] | 0.83 [0.40;1.62] |
1.45 [1.33;1.57]
|
Increasing | 0.99 [0.90;1.08] |
0.73 [0.66;0.81]
|
1.19 [1.05;1.34]
|
1.21 [1.02;1.43]
|
0.89 [0.83;0.94]
|
Hospitalized during follow-up | |||||
For diabetes and its complications | 1.05 [0.94;1.16] |
1.23 [1.11;1.37]
| 1.01 [0.88;1.15] | 1.02 [0.85;1.22] | 1.05 [1.00;1.11] |
For influenza and its complications |
1.32 [1.16;1.48]
|
1.44 [1.22;1.67]
|
1.46 [1.20;1.75]
| 1.30 [0.91;1.81] | 0.98 [0.87;1.09] |
Healthcare utilization | |||||
Frequent consultations during follow-up, with: | |||||
General practitioner |
1.92 [1.76;2.07]
| 1.02 [0.91;1.14] | 0.95 [0.83;1.07] |
0.80 [0.66;0.96]
|
0.85 [0.80;0.90]
|
Endocrinologist |
0.77 [0.65;0.91]
|
0.70 [0.59;0.83]
|
0.82 [0.69;0.97]
|
0.64 [0.49;0.83]
|
0.84 [0.78;0.91]
|
Cardiologist | 1.00 [0.90;1.11] |
0.79 [0.69;0.92]
| 0.87 [0.74;1.01] |
0.71 [0.55;0.91]
|
0.79 [0.73;0.86]
|
Change of general practitioner during follow-up |
0.73 [0.66;0.81]
| 0.98 [0.89;1.08] | 0.94 [0.84;1.05] | 1.13 [0.97;1.31] |
0.93 [0.88;0.97]
|